Patients with relapsed/refractory advanced/metastatic ovarian cancer (aOC) research hub

A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours

This study is testing a new drug called TAX2 for advanced cancers like ovarian, bowel, and pancreatic cancer, and melanoma, when other treatments haven't worked. It will first check if the drug is safe and what dose to use, then look at how well it works against the cancer.